Loading…
Selective enrichment and detection of PD-L1 positive extracellular vesicles derived from human plasma and patient derived tumor cells
Recent studies reported that the level of PD-L1 carried by extracellular vesicles (EVs) could distinguish the presence of tumors and had a good correlation with the response to immunotherapy. In this manuscript, we developed an EV-TdT assay for isolation and detection of PD-L1+ EVs. PD-L1+ EVs were...
Saved in:
Published in: | Sensors and actuators. B, Chemical Chemical, 2023-02, Vol.377, p.133086, Article 133086 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Recent studies reported that the level of PD-L1 carried by extracellular vesicles (EVs) could distinguish the presence of tumors and had a good correlation with the response to immunotherapy. In this manuscript, we developed an EV-TdT assay for isolation and detection of PD-L1+ EVs. PD-L1+ EVs were directly captured from biological samples by PD-L1 antibodies immobilized on the magnetic beads (MBs), then combined with cholesterol modified DNA probes, which initiated the terminal deoxynucleotidyl transferase (TdT) to amplify the signal of PD-L1+ EVs. The EV-TdT assay enables selective enrichment of PD-L1+ EVs in low-content samples, such as blood and excreta of small amounts of primary tumor cells. Moreover, it can evaluate the relative abundance of PD-L1+ EVs in the total population, by this way, we observed that PD-L1+ EVs were more abundant in the extracellular microenvironment of primary tumor cells than in human plasma, indicating that quite a bit of PD-L1+ EVs were derived from tumor cells. The EV-TdT assay has been proven a practical method for detection of PD-L1+ EVs and is greatly potential as an alternative to existing assays for screening immunotherapy benefit populations. |
---|---|
ISSN: | 0925-4005 1873-3077 |
DOI: | 10.1016/j.snb.2022.133086 |